Literature DB >> 6087867

Actual growth rate and tumour cell proliferation in human pulmonary neoplasms.

K M Kerr, D Lamb.   

Abstract

Measurement of the Doubling Times [DT] for 27 human pulmonary neoplasms have been made. Squamous and large cell tumours had a wide range of values for DT whereas for small cell undifferentiated carcinoma, and possibly large cell undifferentiated carcinomata without stratification, the range was narrower. Mean DT for different primary bronchogenic carcinoma groups were: Squamous cell 146 days, Adenocarcinoma 72 days, Small cell 66 days, and Large Cell 111 days. The number of adenocarcinomata is very small in number and our value of 72 days is probably not representative of this group of tumours. Relationship between DT and tumour differentiation was difficult to identify in our series. Of these 27 a unique series of 17 have parallel data on DT and Potential Doubling Time (DTpot) and the Cell Loss Factor [0] calculated. Great discrepancy between DT and DTpot existed in each case and cell loss was high, ranging from 54% to 99%. All primary bronchogenic carcinomata had cell loss of greater than 70%; in almost two thirds of these cases the value was 90% or more. All undifferentiated tumours and a majority of poorly differentiated tumours had cell loss of 90% or more. As cell loss increased, tumour thymidine labelling index (TLI) increased and the tumours tended to be less well differentiated. The relationship, if any, between cell loss and DT was unclear.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6087867      PMCID: PMC1976798          DOI: 10.1038/bjc.1984.181

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  The relationship between growth rate, labelling index and histological type of human solid tumours.

Authors:  E P Malaise; N Chavaudra; M Tubiana
Journal:  Eur J Cancer       Date:  1973-04       Impact factor: 9.162

2.  Relationship between tumor doubling time and anatomoclinical features in 50 measurable pulmonary cancers.

Authors:  P Chahinian
Journal:  Chest       Date:  1972-04       Impact factor: 9.410

3.  Cell kinetic studies in patients with small cell carcinoma of the lung.

Authors:  F M Muggia; S K Krezoski; H H Hansen
Journal:  Cancer       Date:  1974-11       Impact factor: 6.860

4.  Relation between the pathological nature and the growth rate of human tumors.

Authors:  A Charbit; E P Malaise; M Tubiana
Journal:  Eur J Cancer       Date:  1971-08       Impact factor: 9.162

5.  The role of cellular immunity in control of neoplasia.

Authors:  G Bone; R Camplejohn
Journal:  Br J Surg       Date:  1973-10       Impact factor: 6.939

6.  Cell kinetics and growth of squamous cell carcinomas in man.

Authors:  F Bresciani; R Paoluzi; M Benassi; C Nervi; C Casale; E Ziparo
Journal:  Cancer Res       Date:  1974-09       Impact factor: 12.701

7.  Growth rate versus prognosis in resected primary bronchogenic carcinomas.

Authors:  J A Meyer
Journal:  Cancer       Date:  1973-06       Impact factor: 6.860

8.  Asymptomatic solitary pulmonary nodules. Host survival, tumor size, and growth rate.

Authors:  J D Steele; P Buell
Journal:  J Thorac Cardiovasc Surg       Date:  1973-01       Impact factor: 5.209

9.  The cell cycle in tumours: an examination of data gained by the technique of labelled mitoses.

Authors:  G G Steel
Journal:  Cell Tissue Kinet       Date:  1972-01

10.  Cell proliferation in human melanoma.

Authors:  S Shirakawa; J K Luce; I Tannock; E Frei
Journal:  J Clin Invest       Date:  1970-06       Impact factor: 14.808

View more
  21 in total

Review 1.  Definitive radiotherapy in locally advanced non-small cell lung cancer: dose and fractionation.

Authors:  Nergiz Dağoğlu; Şule Karaman; Alptekin Arifoğlu; Seden Küçücük; Ethem N Oral
Journal:  Balkan Med J       Date:  2014-12-01       Impact factor: 2.021

2.  Spontaneous death of rat chloroleukaemia cells induced by an endogenous growth inhibitor.

Authors:  T Rytömaa; K Grip-Rytömaa
Journal:  Cell Prolif       Date:  2017-12-10       Impact factor: 6.831

3.  Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.

Authors:  Audrey Mauguen; Cécile Le Péchoux; Michele I Saunders; Steven E Schild; Andrew T Turrisi; Michael Baumann; William T Sause; David Ball; Chandra P Belani; James A Bonner; Aleksander Zajusz; Suzanne E Dahlberg; Matthew Nankivell; Sumithra J Mandrekar; Rebecca Paulus; Katarzyna Behrendt; Rainer Koch; James F Bishop; Stanley Dische; Rodrigo Arriagada; Dirk De Ruysscher; Jean-Pierre Pignon
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

4.  Repopulation of interacting tumor cells during fractionated radiotherapy: stochastic modeling of the tumor control probability.

Authors:  Hatim Fakir; Lynn Hlatky; Huamin Li; Rainer Sachs
Journal:  Med Phys       Date:  2013-12       Impact factor: 4.071

5.  Tumour fragment spheroids from human non-small-cell lung cancer maintained in organ culture.

Authors:  L Fjellbirkeland; R Bjerkvig; O D Laerum
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

6.  Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes.

Authors:  M J Arends; A H McGregor; A H Wyllie
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

7.  Potential doubling time and tumour doubling time in meningiomas and neurinomas.

Authors:  S Nakasu; Y Nakasu; M Nakajima; M Yokoyama; M Matsuda; J Handa
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

8.  Small cell lung cancer doubling time and its effect on clinical presentation: a concise review.

Authors:  Kassem Harris; Inga Khachaturova; Basem Azab; Theodore Maniatis; Srujitha Murukutla; Michel Chalhoub; Hassan Hatoum; Thomas Kilkenny; Dany Elsayegh; Rabih Maroun; Homam Alkaied
Journal:  Clin Med Insights Oncol       Date:  2012-05-08

9.  A comparison of patient survival and tumour growth kinetics in human bronchogenic carcinoma.

Authors:  K M Kerr; D Lamb
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

10.  Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy.

Authors:  Philip K Maini; Alexander R A Anderson; Maximilian A R Strobl; Jeffrey West; Yannick Viossat; Mehdi Damaghi; Mark Robertson-Tessi; Joel S Brown; Robert A Gatenby
Journal:  Cancer Res       Date:  2020-11-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.